Mutation-Derived Neoantigen Specific T cell Responses in Multiple Myeloma

In this study we show that neoantigens identified in MM are immunogenic and can elicit T cell specific responses, that the mutation burden and neo-antigen burden increases in relapsed MM patients compared to newly diagnosed patients, and that shared neoantigens are predicted in oncogenic driver genes in newly diagnosed and relapsed MM patients. Our data suggest that expansion of neoantigen specific T cell responses may serve as direct pharmacodynamics biomarkers of immunotherapeutic interventions in myeloma and shared neoantigens could be targeted for “off-the-shelf” approaches.